Sysmex Asia Pacific Pte Ltd. (Location: Singapore, President and CEO: Frank Buescher) announces that the Company has begun providing direct sales and support in India for Hematology Business. With more than 1.3 billion people, India is the world’s second most populous nation, after China, and the country’s real GDP continues to grow significantly. In addition […]
Sysmex (Thailand) Co., Ltd has successfully passed the audit for certification to ISO 9001:2015 for sales, trading, distribution, installation and servicing of clinical diagnostic equipment and health care IT products for laboratories, hospitals and healthcare organisations. As well as the import, storage and distribution of diagnostic instrumentation reagents and consumables. ISO9001:2015 certification is an international […]
Sysmex Launches New Products in the Hemostasis Field: Automated Blood Coagulation Analyzers CN-6000 and CN-3000 -Making Testing Even More Efficient and of Higher Quality through Higher Levels of Productivity, Reliability, and Operability
Sysmex Wins the Encouragement Prize for the First Time in the 6th WICI Japan Award for Excellence in Integrated Reporting
With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement
-Aiming to Prevent Atherosclerosis-Related Diseases and Provide Treatment Opportunities-
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the third consecutive year.
We are happy to announce the launch of the dedicated calibrators and controls for Edoxaban which are to be used with Biophen DiXal and Biophen Heparin (LRT). With this new addition, we now have a complete portfolio for direct oral anticoagulants (DOACs) measurement.
Sysmex Corporation has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.
Sysmex Corporation, the Foundation for Biomedical Research and Innovation at Kobe and Kyoto University have begun joint research related to the Drug Discovery Innovation Program: Developing Technologies for Diagnosing Immunological Diseases, which the Foundation is promoting. Through joint research, the three organizations aim to create a diagnostic system that will enable the early detection of autoimmune disease and chronic inflammatory disease.